Tarsus Pharmaceuticals, Inc.
TARS
$58.85
$2.243.96%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -91.99M | -104.94M | -115.55M | -134.34M | -150.07M |
| Total Depreciation and Amortization | 1.63M | 1.42M | 1.23M | 1.14M | 1.10M |
| Total Amortization of Deferred Charges | 552.00K | 507.00K | 482.00K | 455.00K | 427.00K |
| Total Other Non-Cash Items | 25.02M | 26.61M | 26.98M | 25.80M | 24.39M |
| Change in Net Operating Assets | -16.08M | 10.52M | 3.84M | 6.76M | 261.00K |
| Cash from Operations | -80.87M | -65.89M | -83.03M | -100.18M | -123.89M |
| Capital Expenditure | -1.95M | -1.98M | -1.57M | -1.50M | -1.59M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -141.15M | -129.93M | -197.63M | -120.28M | -75.94M |
| Cash from Investing | -143.09M | -131.91M | -199.20M | -121.77M | -77.53M |
| Total Debt Issued | 0.00 | 75.00M | 75.00M | 75.00M | 80.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 142.12M | 142.85M | 105.69M | 122.52M | 221.74M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -39.00K | -35.40M | -26.04M | -26.04M | -26.00M |
| Cash from Financing | 142.08M | 182.45M | 154.66M | 171.49M | 275.74M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -81.88M | -15.36M | -127.57M | -50.46M | 74.32M |